Security
Supernus, Inc. Common Stock · SUPN
SUPNNASDAQCommon stockCurrentCIK 1356576Updated Nov 6, 2026
Name history
SUPERNUS PHARMACEUTICALS INC · through Jun 12, 2019
SUPN price & chart
Loading TradingView…
NASDAQ:SUPN on TradingView ↗About the company
Supernus, Inc. is a leading, diversified biopharmaceutical company focused on developing and commercializing treatments for patients living with central nervous system (CNS) diseases. Our commercial portfolio includes approved treatments designed to support individuals navigating opioid use disorder (OUD), attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson’s disease (PD) for those receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. Backed by strong commercial capabilities and scientific expertise, we are committed to continuous innovation, advancing a robust pipeline of novel product candidates to deliver meaningful outcomes for CNS patients.
In the news
Shareholder Alert: Ademi LLP investigates whether Supernus Pharmaceuticals, Inc. is obtaining a Fair Price for Public Shareholders ↗
Supernus Announces Second Quarter 2026 Financial Results ↗
ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Sage Therapeutics, Inc. News provided by Rowley Law PLLC Jun 16, 2025, 17:31 ET Share this article Share to X Share this article Share to X NEW YORK , June 16, 2025 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities l ↗
Recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 1,419,754,000Source | 1,342,701,000Source | 1,428,109,000Source | 1,382,405,000Source | 1,315,829,000Source | 1,500,725,000Source | 1,347,290,000Source | 1,304,090,000Source | 1,452,648,000Source | 1,368,073,000Source | 1,277,673,000Source | 1,702,508,000Source |
| Property, Plant and Equipment, NetUSD | 10,627,000Source | 11,876,000Source | 10,197,000Source | 11,069,000Source | 12,274,000Source | 10,042,000Source | 11,338,000Source | 12,969,000Source | 10,531,000Source | 11,545,000Source | 13,530,000Source | 15,173,000Source |
| GoodwillUSD | 119,080,000Source | 117,019,000Source | 119,431,000Source | 117,019,000Source | 117,019,000Source | 120,668,000Source | 117,019,000Source | 117,019,000Source | 124,882,000Source | 117,019,000Source | 117,019,000Source | 117,019,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 623,481,000Source | 540,156,000Source | 469,459,000Source | 481,307,000Source | 559,644,000Source | 549,712,000Source | 502,126,000Source | 579,752,000Source | 569,456,000Source | 521,912,000Source | 599,889,000Source | 702,463,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 151,371,000Source | 31,673,000Source | 179,953,000Source | 144,711,000Source | 52,089,000Source | 184,869,000Source | 115,848,000Source | 63,401,000Source | 128,448,000Source | 69,331,000Source | 75,054,000Source | 93,120,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 171,254,000Source | 145,408,000Source | 211,656,000Source | 140,831,000Source | 152,494,000Source | 182,183,000Source | 145,640,000Source | 147,734,000Source | 187,802,000Source | 142,077,000Source | 144,155,000Source | 165,497,000Source |
| Inventory, NetUSD | 107,100,000Source | 63,981,000Source | 107,027,000Source | 44,023,000Source | 68,155,000Source | 110,771,000Source | 49,423,000Source | 75,079,000Source | 112,480,000Source | 54,293,000Source | 77,408,000Source | 91,541,000Source |
| Assets, CurrentUSD | 593,891,000Source | 640,003,000Source | 723,496,000Source | 738,866,000Source | 591,002,000Source | 731,580,000Source | 687,584,000Source | 544,321,000Source | 644,182,000Source | 686,070,000Source | 493,113,000Source | 734,151,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 62,078,000Source | 27,404,000Source | 55,849,000Source | 31,416,000Source | 23,166,000Source | 78,094,000Source | 28,931,000Source | 23,772,000Source | 65,325,000Source | 36,088,000Source | 16,676,000Source | 15,779,000Source |
| Operating Lease, Right-of-Use AssetUSD | 28,761,000Source | 26,086,000Source | 25,425,000Source | 21,881,000Source | 27,766,000Source | 26,397,000Source | 22,724,000Source | 29,748,000Source | 26,712,000Source | 24,477,000Source | 28,994,000Source | 28,904,000Source |
| Other Assets, NoncurrentUSD | 62,432,000Source | 33,647,000Source | 55,015,000Source | 27,963,000Source | 35,890,000Source | 56,453,000Source | 29,223,000Source | 38,367,000Source | 63,796,000Source | 31,527,000Source | 37,505,000Source | 39,806,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 370,087,000Source | 335,551,000Source | 396,883,000Source | 318,505,000Source | 358,375,000Source | 423,920,000Source | 316,585,000Source | 374,924,000Source | 390,934,000Source | 332,340,000Source | 356,157,000Source | 816,304,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 57,000Source | 55,000Source | 58,000Source | 56,000Source | 55,000Source | 58,000Source | 56,000Source | 55,000Source | 57,000Source | 56,000Source | 55,000Source | 54,000Source |
| Additional Paid in CapitalUSD | 527,700,000Source | 465,919,000Source | 574,094,000Source | 496,946,000Source | 455,170,000Source | 561,419,000Source | 486,209,000Source | 446,960,000Source | 543,825,000Source | 479,440,000Source | 439,493,000Source | 408,115,000Source |
| Retained Earnings (Accumulated Deficit)USD | 521,981,000Source | 541,098,000Source | 457,212,000Source | 567,098,000Source | 502,601,000Source | 515,583,000Source | 544,599,000Source | 482,685,000Source | 517,876,000Source | 556,426,000Source | 482,561,000Source | 481,245,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | -71,000Source | 78,000Source | -138,000Source | -200,000Source | -372,000Source | -255,000Source | -159,000Source | -534,000Source | -44,000Source | -189,000Source | -593,000Source | -3,210,000Source |
| Stockholders' Equity Attributable to ParentUSD | 1,049,667,000Source | 1,007,150,000Source | 1,031,226,000Source | 1,063,900,000Source | 957,454,000Source | 1,076,805,000Source | 1,030,705,000Source | 929,166,000Source | 1,061,714,000Source | 1,035,733,000Source | 921,516,000Source | 886,204,000Source |
| Liabilities and EquityUSD | 1,419,754,000Source | 1,342,701,000Source | 1,428,109,000Source | 1,382,405,000Source | 1,315,829,000Source | 1,500,725,000Source | 1,347,290,000Source | 1,304,090,000Source | 1,452,648,000Source | 1,368,073,000Source | 1,277,673,000Source | 1,702,508,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 330,629,000Source | 291,508,000Source | 347,378,000Source | 286,360,000Source | 308,656,000Source | 373,929,000Source | 281,772,000Source | 314,554,000Source | 338,171,000Source | 292,397,000Source | 290,196,000Source | 687,958,000Source |
| Operating Lease, Liability, CurrentUSD | 10,790,000Source | 9,227,000Source | 10,743,000Source | 7,391,000Source | 9,683,000Source | 10,636,000Source | 5,937,000Source | 9,133,000Source | 10,612,000Source | 6,889,000Source | 8,331,000Source | 6,791,000Source |
| Accounts Payable, CurrentUSD | 8,177,000Source | 6,392,000Source | 5,593,000Source | 8,215,000Source | 4,628,000Source | 10,171,000Source | 7,072,000Source | 14,397,000Source | 2,677,000Source | 4,587,000Source | 1,964,000Source | 10,543,000Source |
| Operating Lease, Liability, NoncurrentUSD | 31,422,000Source | 28,926,000Source | 29,427,000Source | 24,383,000Source | 30,294,000Source | 30,267,000Source | 26,368,000Source | 32,994,000Source | 30,365,000Source | 27,382,000Source | 33,196,000Source | 35,998,000Source |
| Deferred Income Tax Liabilities, NetUSD | 0Source | 7,364,000Source | — | 0Source | 11,440,000Source | — | 981,000Source | 19,501,000Source | 0Source | 4,961,000Source | 24,963,000Source | 49,809,000Source |
| Other Liabilities, NoncurrentUSD | 7,823,000Source | 7,350,000Source | 19,872,000Source | 7,762,000Source | 7,288,000Source | 19,518,000Source | 7,464,000Source | 6,899,000Source | 22,192,000Source | 7,600,000Source | 6,422,000Source | 8,692,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 108,613,000Source | 75,803,000Source | 108,458,000Source | 77,739,000Source | 82,611,000Source | 101,244,000Source | 76,891,000Source | 86,402,000Source | 107,800,000Source | 76,352,000Source | 79,569,000Source | 96,342,000Source |
| Deferred Tax Liabilities, NetUSD | — | — | — | — | — | — | — | — | — | 4,961,000Source | 24,963,000Source | 49,809,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation, Depletion and AmortizationUSD | — | — | — | — | — | — | 26,132,000Source | 20,383,000Source | 91,563,000Source | 80,414,000Source | 84,859,000Source | 85,543,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 8,480,000Source | 8,068,000Source | 33,051,000Source | 27,755,000Source | 26,759,000Source | 17,568,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -5,619,000Source | 3,563,000Source | 22,304,000Source | -2,078,000Source | -18,765,000Source | 16,366,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | 105,000Source | -4,731,000Source | 7,502,000Source | -15,806,000Source | -6,110,000Source | 17,858,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | 5,916,000Source | -3,990,000Source | 5,206,000Source | -20,136,000Source | -25,714,000Source | -26,324,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | 66,524,000Source | 30,599,000Source | 47,331,000Source | 171,951,000Source | 111,085,000Source | 116,826,000Source |
| Cash flows from investing activities: | ||||||||||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | — | — | — | — | — | — | — | — | 293,093,000Source | — | — | 0Source |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | -19,218,000Source | 37,317,000Source | 4,106,000Source | -189,867,000Source | 268,729,000Source | -216,663,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 0Source | 327,000Source | 1,338,000Source | 725,000Source | 551,000Source | — |
| Cash flows from financing activities: | ||||||||||||
| Payment, Tax Withholding, Share-based Payment ArrangementUSD | — | — | — | — | — | — | 4,555,000Source | 3,341,000Source | 4,229,000Source | 2,715,000Source | 1,990,000Source | — |
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | 9,115,000Source | -21,399,000Source | 9,130,000Source | 12,193,000Source | -397,880,000Source | -10,477,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | 56,421,000Source | 46,517,000Source | 60,567,000Source | -5,723,000Source | -18,066,000Source | -110,314,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | — | — | 152,821,000Source | 31,673,000Source | 181,403,000Source | 144,711,000Source | 186,319,000Source | 115,848,000Source | 129,898,000Source | 69,331,000Source | 75,054,000Source | 93,120,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 1,946,000Source | 2,516,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | -412,000Source | 274,000Source | 16,051,000Source | 53,254,000Source | 36,602,000Source | 16,200,000Source |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 30,745,000Source | 7,674,000Source | 8,640,000Source | 7,507,000Source | 8,480,000Source | 8,068,000Source | 55,972,000Source | 27,755,000Source | 26,759,000Source | 17,568,000Source |
| Amortization of Debt Issuance Costs and DiscountsUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 532,000Source | 2,112,000Source |
| Amortization of Intangible AssetsUSD | — | — | 24,325,000Source | 19,488,000Source | 25,333,000Source | 20,819,000Source | 25,644,000Source | 19,786,000Source | 89,456,000Source | 77,977,000Source | 82,385,000Source | 82,630,000Source |
| DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecordedUSD | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | — |
| Debt Securities, Available-for-sale, Realized Gain (Loss)USD | — | — | — | — | — | — | 21,000Source | -9,000Source | -439,000Source | — | — | — |
| Equity Method Investment, Realized Gain (Loss) on DisposalUSD | — | — | — | — | — | — | — | — | — | 0Source | 0Source | 12,888,000Source |
| GoodwillUSD | — | — | 119,080,000Source | 117,019,000Source | 119,431,000Source | 117,019,000Source | 120,668,000Source | 117,019,000Source | 124,882,000Source | 117,019,000Source | 117,019,000Source | 117,019,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | — |
| Impairment of Intangible Assets (Excluding Goodwill)USD | — | — | — | — | 54,919,000Source | 0Source | — | — | 0Source | 0Source | 20,189,000Source | — |
| Income Tax Expense (Benefit)USD | — | — | -12,837,000Source | 6,446,000Source | 723,000Source | -5,830,000Source | -3,657,000Source | 5,996,000Source | -10,480,000Source | 24,005,000Source | 1,453,000Source | 32,000Source |
| InterestExpenseNonoperatingUSD | — | — | — | 0Source | 2,315,000Source | 0Source | — | — | 0Source | 0Source | 2,415,000Source | — |
| Inventory Write-downUSD | — | — | — | — | — | — | 1,815,000Source | 547,000Source | 1,926,000Source | 8,876,000Source | 8,023,000Source | — |
| Net Income (Loss) Attributable to ParentUSD | — | — | -45,117,000Source | 38,497,000Source | -58,371,000Source | 22,499,000Source | -2,293,000Source | -11,827,000Source | -38,550,000Source | 73,865,000Source | 1,316,000Source | 60,711,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | -58,371,000Source | 22,499,000Source | -2,293,000Source | -11,827,000Source | -38,550,000Source | 73,865,000Source | 1,316,000Source | 64,267,000Source |
| Nonoperating Income (Expense)USD | — | — | 2,277,000Source | 4,098,000Source | 315,000Source | 4,528,000Source | 2,382,000Source | 4,425,000Source | 13,253,000Source | 16,204,000Source | 8,038,000Source | — |
| Other Nonoperating Income (Expense)USD | — | — | 2,277,000Source | 4,098,000Source | — | 4,528,000Source | 2,382,000Source | 4,425,000Source | 13,253,000Source | 16,204,000Source | 10,453,000Source | 14,619,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | — | — | — | 13,670,000Source | 2,042,000Source | 37,616,000Source | 14,908,000Source | 6,610,000Source | 12,423,000Source |
| Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-saleUSD | — | — | — | — | — | — | 59,220,000Source | 156,201,000Source | 774,478,000Source | 498,871,000Source | 370,901,000Source | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | 34,900,000Source | 6,800,000Source | 4,300,000Source | — |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 192,103,000Source | 175,689,000Source | 219,058,000Source | 165,453,000Source | 207,705,000Source | 149,824,000Source | 718,952,000Source | 661,817,000Source | 607,521,000Source | 667,238,000Source |
| Cost of RevenueUSD | — | — | 18,965,000Source | 17,583,000Source | 33,669,000Source | 16,827,000Source | 23,391,000Source | 15,763,000Source | 74,562,000Source | 77,906,000Source | 83,779,000Source | — |
| Gross Profit (Calculated) · Derived | — | — | — | — | — | — | — | — | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | — | — | 179,678,000Source | 69,753,000Source | 133,637,000Source | 93,551,000Source | 125,173,000Source | 89,944,000Source | 485,563,000Source | 321,582,000Source | 336,361,000Source | 377,221,000Source |
| Operating Income (Loss)USD | — | — | -60,231,000Source | 40,845,000Source | -57,963,000Source | 12,141,000Source | -8,332,000Source | -10,256,000Source | -62,283,000Source | 81,666,000Source | -5,269,000Source | 46,124,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 2,277,000Source | 4,098,000Source | — | 4,528,000Source | 2,382,000Source | 4,425,000Source | 13,253,000Source | 16,204,000Source | 10,453,000Source | 14,619,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | -57,954,000Source | 44,943,000Source | -57,648,000Source | 16,669,000Source | -5,950,000Source | -5,831,000Source | -49,030,000Source | 97,870,000Source | 2,769,000Source | 60,743,000Source |
| Income Tax Expense (Benefit)USD | — | — | -12,837,000Source | 6,446,000Source | 723,000Source | -5,830,000Source | -3,657,000Source | 5,996,000Source | -10,480,000Source | 24,005,000Source | 1,453,000Source | 32,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -45,117,000Source | 38,497,000Source | -58,371,000Source | 22,499,000Source | -2,293,000Source | -11,827,000Source | -38,550,000Source | 73,865,000Source | 1,316,000Source | 60,711,000Source |
| Earnings Per Share, BasicUSD per share | — | — | -0.8Source | 0.7Source | -1.01Source | 0.4Source | -0.04Source | -0.21Source | -0.68Source | 1.34Source | 0.02Source | 1.13Source |
| Earnings Per Share, DilutedUSD per share | — | — | -0.8Source | 0.69Source | -1.01Source | 0.4Source | -0.04Source | -0.21Source | -0.68Source | 1.32Source | 0.02Source | 1.04Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 56,552,741Source | 55,149,760Source | 58,070,378Source | 56,024,771Source | 57,647,548Source | 55,864,692Source | 56,451,136Source | 55,100,063Source | 54,536,281Source | 53,665,143Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 56,552,741Source | 56,016,350Source | 58,070,378Source | 56,643,189Source | 57,647,548Source | 55,864,692Source | 56,451,136Source | 55,958,537Source | 55,506,828Source | 61,679,800Source |
| Interest Expense (non-operating)USD | — | — | — | 0Source | 2,315,000Source | 0Source | — | — | 0Source | 0Source | 2,415,000Source | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | 24,325,000Source | 19,488,000Source | 25,333,000Source | 20,819,000Source | 25,644,000Source | 19,786,000Source | 89,456,000Source | 77,977,000Source | 82,385,000Source | 82,630,000Source |
| Cost of Goods and Service, Excluding Depreciation, Depletion, and AmortizationUSD | — | — | — | — | — | — | — | — | — | — | — | 87,221,000Source |
| Costs and ExpensesUSD | — | — | 252,334,000Source | 134,844,000Source | 277,021,000Source | 153,312,000Source | 216,037,000Source | 160,080,000Source | 781,235,000Source | 580,151,000Source | 612,790,000Source | 621,114,000Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | -15,686,000Source | — | — | — |
| DebtSecuritiesAvailableForSaleExcludingAccruedInterestAllowanceForCreditLossNotPreviouslyRecordedUSD | — | — | — | — | — | — | 0Source | 0Source | 0Source | 0Source | 0Source | — |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | 500,000Source | 600,000Source | 400,000Source | 500,000Source | 500,000Source | 600,000Source | 2,100,000Source | 2,400,000Source | 2,500,000Source | 3,000,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 0Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | -48,825,000Source | — | — | — |
| Interest Expense, DebtUSD | — | — | — | — | — | — | — | — | 0Source | 0Source | 1,321,000Source | 4,654,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | — | — | — | — | -58,371,000Source | 22,499,000Source | -2,293,000Source | -11,827,000Source | -38,550,000Source | 73,865,000Source | 1,316,000Source | 64,267,000Source |
| Nonoperating Income (Expense)USD | — | — | 2,277,000Source | 4,098,000Source | 315,000Source | 4,528,000Source | 2,382,000Source | 4,425,000Source | 13,253,000Source | 16,204,000Source | 8,038,000Source | — |
| Research and Development ExpenseUSD | — | — | 29,366,000Source | 29,036,000Source | 29,463,000Source | 22,115,000Source | 39,438,000Source | 26,927,000Source | 106,235,000Source | 108,796,000Source | 91,593,000Source | 74,552,000Source |
| Interest and Other Income | — | — | — | — | —Source | —Source | — | — | — | — | — | — |
Filing attachments
tm2628719d1_ex99-1.htm · 8-K · 2026-11-02
Exhibit 99.1 Supernus and Indivior Complete Merger Creating a Diversified CNS Biopharmaceutical Leader Merger positions Supernus as a leading diversified central nervous system (CNS) biopharmaceutical company with a broad portfolio of marketed medicines, enhanced financial flexibility and a differentiated pipeline Significantly enhances cash flow profile and scale, unlocking greater capacity to resource growth-driving products, advance CNS pipeline, and pursue strategic opportunit…
Read attachment ↗tm2628092d1_ex99-1.htm · 8-K · 2026-10-22
Exhibit 99.1 Supernus Announces Orphan Drug Exclusivity for ONAPGO™ (apomorphine HCl) Orphan-drug exclusivity provides seven years of market exclusivity for ONAPGO Additionally, the Company submitted an sNDA to the FDA for a second supplier for ONAPGO, with potential approval by mid-year 2027 ROCKVILLE, Md., October 21, 2026 - Supernus, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) disease…
Read attachment ↗tm2622009d7_ex99-1.htm · DEFA14A · 2026-08-03
Exhibit 99.1 Filed by: Supernus Pharmaceuticals, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Supernus Pharmaceuticals, Inc. Commission File No. 001-35518 Date: August 3, 2026
Read attachment ↗tm2622009d7_ex99-2.htm · DEFA14A · 2026-08-03
Exhibit 99.2 Filed by: Supernus Pharmaceuticals, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Supernus Pharmaceuticals, Inc. Commission File No.: 001-35518 Date: August 3, 2026 August, 3, 2026 ─────────────────── For Internal Use Only, Do Not Forward Dear Colleagues, Today, we announced that Supernus and Indivior have entered into an agreement to combine our companies in…
Read attachment ↗tm2622009d7_ex99-1.htm · 425 · 2026-08-03
Exhibit 99.1 Filed by: Supernus Pharmaceuticals, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Supernus Pharmaceuticals, Inc. Commission File No. 001-35518 Date: August 3, 2026
Read attachment ↗tm2622009d7_ex99-2.htm · 425 · 2026-08-03
Exhibit 99.2 Filed by: Supernus Pharmaceuticals, Inc. Pursuant to Rule 425 under the Securities Act of 1933 and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934 Subject Company: Supernus Pharmaceuticals, Inc. Commission File No.: 001-35518 Date: August 3, 2026 August, 3, 2026 ─────────────────── For Internal Use Only, Do Not Forward Dear Colleagues, Today, we announced that Supernus and Indivior have entered into an agreement to combine our companies in…
Read attachment ↗